6.
Kim R, Chung V, Alese O, El-Rayes B, Li D, Al-Toubah T
. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncol. 2020; 6(6):888-894.
PMC: 7193528.
DOI: 10.1001/jamaoncol.2020.0930.
View
7.
Wu T, Madireddi S, de Almeida P, Banchereau R, Chen Y, Chitre A
. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020; 579(7798):274-278.
DOI: 10.1038/s41586-020-2056-8.
View
8.
Jachimowicz R, Klapper W, Glehr G, Muller H, Haverkamp H, Thorns C
. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. Leukemia. 2021; 35(12):3589-3593.
PMC: 8632672.
DOI: 10.1038/s41375-021-01314-1.
View
9.
Yarchoan M, Gane E, Marron T, Perales-Linares R, Yan J, Cooch N
. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nat Med. 2024; 30(4):1044-1053.
PMC: 11031401.
DOI: 10.1038/s41591-024-02894-y.
View
10.
Bruggemann M, Kotrova M, Knecht H, Bartram J, Boudjogrha M, Bystry V
. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 2019; 33(9):2241-2253.
PMC: 6756028.
DOI: 10.1038/s41375-019-0496-7.
View
11.
Ma Y, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G
. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood. 2007; 111(4):2339-46.
DOI: 10.1182/blood-2007-09-112128.
View
12.
Muller-Meinhard B, Seifert N, Grund J, Reinke S, Yalcin F, Kaul H
. Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma. Hemasphere. 2024; 8(6):e84.
PMC: 11145947.
DOI: 10.1002/hem3.84.
View
13.
Ansell S, Brockelmann P, von Keudell G, Lee H, Santoro A, Zinzani P
. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023; 7(20):6266-6274.
PMC: 10589773.
DOI: 10.1182/bloodadvances.2023010334.
View
14.
Nijland M, Veenstra R, Visser L, Xu C, Kushekhar K, van Imhoff G
. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncoimmunology. 2017; 6(4):e1295202.
PMC: 5414870.
DOI: 10.1080/2162402X.2017.1295202.
View
15.
Jachimowicz R, Pieper L, Reinke S, Gontarewicz A, Plutschow A, Haverkamp H
. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica. 2020; 106(6):1684-1692.
PMC: 8168506.
DOI: 10.3324/haematol.2019.243287.
View
16.
Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L
. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71.
PMC: 4246418.
DOI: 10.1038/nature13954.
View
17.
Lynch R, Ujjani C, Poh C, Warren E, Smith S, Shadman M
. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023; 141(21):2576-2586.
PMC: 10273164.
DOI: 10.1182/blood.2022019254.
View
18.
Reinke S, Brockelmann P, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F
. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020; 136(25):2851-2863.
DOI: 10.1182/blood.2020008553.
View
19.
Brockelmann P, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth T
. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol. 2022; 41(6):1193-1199.
DOI: 10.1200/JCO.22.02355.
View
20.
Chen X, Yu J, Venkataraman G, Smith S, Chen M, Cooper A
. T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses. Cancer Immunol Res. 2024; 12(3):296-307.
DOI: 10.1158/2326-6066.CIR-23-0547.
View